EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-? Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting

Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-? trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ — EpicentRx, Inc, a clinical-stage biotechnology drug and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks